AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10093094 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust mite antigen analysis
Number of subjects: 0
Study 7529468 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-dose aprotinin (initial dose of 2,000,000 KIU followed by infusion of 500,000 KIU/h)
Number of subjects: 199
Study 7529468 — intervention group
Group type: COMPARATOR
Intervention: Small-dose aprotinin (initial dose of 500,000 KIU followed by infusion of 150,000 KIU/h)
Number of subjects: 199
Study 1697836 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 deamino‐8‐D‐arginine vasopressin (DDAVP) 0.4 micrograms/kg BW
Number of subjects: 16
Study 1697836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 396657 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 30
Study 396657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30955089 — intervention group
Group type: COMPARATOR
Intervention: Traditional (TR: 6 sets of 4 repetitions with 3 min of rest between sets)
Number of subjects: 26
Study 30955089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster (CL: 6 sets of 4 repetitions with 15 s of intra-set rest every two repetitions and 2 min and 45 s of rest between sets)
Number of subjects: 26
Study 30955089 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-repetition rest (IRR: 1 set of 24 repetitions with 39 s of rest between repetitions)
Number of subjects: 26
Study 28712353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention for PTSD (CBT-P), 12-16 sessions
Number of subjects: 183
Study 28712353 — intervention group
Group type: COMPARATOR
Intervention: Breathing retraining and psychoeducation intervention (BRF), 3 sessions
Number of subjects: 183
Study 25999100 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aggressive strategy
Number of subjects: 645
Study 25999100 — intervention group
Group type: COMPARATOR
Intervention: Initially conservative strategy
Number of subjects: 645
Study 25999100 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 645
Study 25999100 — intervention group
Group type: COMPARATOR
Intervention: No revascularization
Number of subjects: 645
Study 22237990 — intervention group
Group type: EXPERIMENTAL
Intervention: Seating force of 10 g
Number of subjects: 45
Study 22237990 — intervention group
Group type: EXPERIMENTAL
Intervention: Seating force of 50 g
Number of subjects: 45
Study 22237990 — intervention group
Group type: EXPERIMENTAL
Intervention: Seating force of 100 g
Number of subjects: 45
Study 22237990 — intervention group
Group type: EXPERIMENTAL
Intervention: Seating force of 500 g
Number of subjects: 45
Study 22237990 — intervention group
Group type: EXPERIMENTAL
Intervention: Seating force of 750 g
Number of subjects: 45
Study 21671496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based quadruple therapy (esomeprazole 20 mg, clarithromycin 0.5 g, amoxicillin 1.0 g, bismuth potassium citrate 220 mg for 7 days)
Number of subjects: 136
Study 21671496 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (esomeprazole 20 mg, clarithromycin 0.5 g, amoxicillin 1.0 g for 7 days)
Number of subjects: 136
Study 19086083 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-start rasagiline treatment
Number of subjects: 404
Study 19086083 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start rasagiline treatment (placebo for 6 months)
Number of subjects: 404
Study 16725133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent polarization immunoassay (FPIA)
Number of subjects: 45
Study 16725133 — intervention group
Group type: COMPARATOR
Intervention: HPLC-tandem mass spectrometry (HPLC-MS)
Number of subjects: 45
Study 15833263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 3
Study 15833263 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 3
Study 15833263 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 3
Study 12077522 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% azelaic acid formulation
Number of subjects: 50
Study 12077522 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ascorbyl glucosamine, 1% kojic acid and alpha‐hydroxyacid esters
Number of subjects: 50
Study 12077522 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized soy extract
Number of subjects: 50
Study 12077522 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical whitening agents
Number of subjects: 50
Study 12077522 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical or faint mottled skin
Number of subjects: 50
Study 10465378 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal gel (1.5 mg oestradiol)
Number of subjects: 27
Study 10465378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet (2 mg oestradiol valerate)
Number of subjects: 27
Study 10465378 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patch (50 microg/24 h)
Number of subjects: 27
Study 8667576 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen and autologous growth factors
Number of subjects: 35
Study 8667576 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional methods)
Number of subjects: 35
Study 2356715 — intervention group
Group type: COMPARATOR
Intervention: Compression applied for 10 minutes (C-10)
Number of subjects: 100
Study 2356715 — intervention group
Group type: COMPARATOR
Intervention: Compression applied for 20 minutes (C-20)
Number of subjects: 100
Study 2356715 — intervention group
Group type: COMPARATOR
Intervention: No compression (Control group)
Number of subjects: 100
Study 475944 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 102
Study 475944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine hydrobromide (0.3 mg)
Number of subjects: 102
Study 475944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 30080727 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Analgesia (EP)
Number of subjects: 83
Study 30080727 — intervention group
Group type: COMPARATOR
Intervention: Abdominal Wound Catheters plus Patient-Controlled Analgesia (AWC-PCA)
Number of subjects: 83
Study 28806502 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 26
Study 28806502 — intervention group
Group type: COMPARATOR
Intervention: Control (no ESS)
Number of subjects: 26
Study 25251893 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil alone (group-R)
Number of subjects: 54
Study 25251893 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-meperidine combination (group-MM)
Number of subjects: 54
Study 23782589 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/day of fish oil (approximately 3.6 g/day of LCn‐3PUFA)
Number of subjects: 40
Study 23782589 — intervention group
Group type: COMPARATOR
Intervention: 6 g/day of corn oil (placebo)
Number of subjects: 40
Study 21717779 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture of Ashi-points plus moxibustion of heat-sensitive points
Number of subjects: 62
Study 21717779 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture of Ashi-points plus TDP irradiation
Number of subjects: 62
Study 19207321 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-particle NASHA filler
Number of subjects: 248
Study 19207321 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-particle NASHA filler
Number of subjects: 248
Study 19207321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fanning injection technique
Number of subjects: 248
Study 19207321 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of NASHA product used
Number of subjects: 248
Study 17161821 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (0.25-2 mg)
Number of subjects: 0
Study 17161821 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (3.5 mg)
Number of subjects: 0
Study 15060237 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn Individualized Developmental Care and Assessment Program (NIDCAP) initiated within 72 hours of ICU admission and continued to 2 weeks corrected for prematurity.
Number of subjects: 30
Study 15060237 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 30
Study 11495165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 158
Study 11495165 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 158
Study 9920537 — intervention group
Group type: EXPERIMENTAL
Intervention: Norgestimate and ethinyl estradiol (0.035 mg ethinyl estradiol plus increasing doses of norgestimate [0.180 mg, 0.215 mg, 0.250 mg]) for 3 weeks followed by 1 week of inactive tablets
Number of subjects: 507
Study 9920537 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for 4 weeks
Number of subjects: 507
Study 7551066 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Counseling
Number of subjects: 0
Study 7551066 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2972549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine di-HCl (10 mg)
Number of subjects: 12
Study 2972549 — intervention group
Group type: COMPARATOR
Intervention: Dexchlorpheniramine maleate (6 mg)
Number of subjects: 12
Study 31640794 — intervention group
Group type: EXPERIMENTAL
Intervention: IPF patients
Number of subjects: 300
Study 30207100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary recruitment maneuver (PRM)
Number of subjects: 113
Study 30207100 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study 27454785 — intervention group
Group type: EXPERIMENTAL
Intervention: VMS-ASIR in DE-CTPA group
Number of subjects: 140
Study 23611305 — intervention group
Group type: EXPERIMENTAL
Intervention: Older cousin with drug abuse (DA)
Number of subjects: 0
Study 23611305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cousin pairs with closer age differences
Number of subjects: 0
Study 23611305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cousin pairs growing up in high geographical proximity
Number of subjects: 0
Study 23611305 — intervention group
Group type: EXPERIMENTAL
Intervention: Male-male cousin pairs
Number of subjects: 0
Study 23611305 — intervention group
Group type: EXPERIMENTAL
Intervention: Older → younger cousin transmission
Number of subjects: 0
Study 22136751 — intervention group
Group type: COMPARATOR
Intervention: Menaquinone-4 (MK-4) 45 mg
Number of subjects: 450
Study 22136751 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (various doses)
Number of subjects: 450
Study 22136751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 22136751 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K status (general)
Number of subjects: 450
Study 20369616 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaxol infusion solution
Number of subjects: 494
Study 20369616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study 17578978 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg before surgery and 200 mg every 12 h for 14 days postoperatively
Number of subjects: 200
Study 17578978 — intervention group
Group type: COMPARATOR
Intervention: Placebo before surgery and matching placebo for 14 days postoperatively
Number of subjects: 200
Study 15589464 — intervention group
Group type: COMPARATOR
Intervention: Fenoldopam infusion at 0.025 microg/kg/min titrated to 0.1 microg/kg/min for 48 hours post-op
Number of subjects: 20
Study 15589464 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody induction (AI) using antithymocyte globulin (AT-G(r))
Number of subjects: 20
Study 12110157 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic and treatment algorithms to optimize antibiotic use in nursing homes
Number of subjects: 0
Study 10099862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (100 mg/day)
Number of subjects: 24
Study 2157313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg
Number of subjects: 10
Study 2157313 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 40 mg
Number of subjects: 10
Study 2157313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg plus Furosemide 40 mg
Number of subjects: 10
Study 446302 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of pulmonary metastases
Number of subjects: 67
Study 446302 — intervention group
Group type: COMPARATOR
Intervention: No surgical intervention
Number of subjects: 67
Study 446302 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobectomy
Number of subjects: 67
Study 446302 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge excision
Number of subjects: 67
Study 446302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonectomy
Number of subjects: 67
Study 446302 — intervention group
Group type: EXPERIMENTAL
Intervention: First filter of haematogenous metastases in the lung
Number of subjects: 67
Study 446302 — intervention group
Group type: EXPERIMENTAL
Intervention: First filter of haematogenous metastases in the liver
Number of subjects: 67
Study 446302 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged interval before recurrence
Number of subjects: 67
Study 446302 — intervention group
Group type: EXPERIMENTAL
Intervention: Short interval before recurrence
Number of subjects: 67
Study 31885341 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual oculomotor training (GOT)
Number of subjects: 120
Study 31885341 — intervention group
Group type: COMPARATOR
Intervention: High-intensity trainings
Number of subjects: 120
Study 30702960 — intervention group
Group type: COMPARATOR
Intervention: Traditional Outline (OUT)
Number of subjects: 31
Study 29513111 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/monocyte adsorptive apheresis (GMA)
Number of subjects: 95
Study 27003645 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS group
Number of subjects: 127
Study 24998014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 328
Study 24998014 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 328
Study 24998014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 328
Study 21556746 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. vitamin D (300,000 IU)
Number of subjects: 120
Study 21556746 — intervention group
Group type: COMPARATOR
Intervention: i.m. placebo
Number of subjects: 120
Study 21556746 — intervention group
Group type: EXPERIMENTAL
Intervention: p.o. vitamin D (300,000 IU)
Number of subjects: 120
Study 21556746 — intervention group
Group type: COMPARATOR
Intervention: p.o. placebo
Number of subjects: 120
Study 20566359 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate 5mg/day for 14 days (group A)
Number of subjects: 86
Study 20566359 — intervention group
Group type: COMPARATOR
Intervention: Folic acid 4mg/day for 14 days (group B)
Number of subjects: 86
Study 17447826 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (specifically olanzapine)
Number of subjects: 0
Study 17447826 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0
Study 17447826 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study 16251617 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified fish sauce (9 mmol (500 mg) Fe/L) for 18 months
Number of subjects: 576
Study 16251617 — intervention group
Group type: COMPARATOR
Intervention: Unfortified fish sauce (Control Group)
Number of subjects: 576
Study 14601477 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance to activated protein C (APC-R)
Number of subjects: 29
Study 14601477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentration
Number of subjects: 29
Study 14601477 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein S activity
Number of subjects: 29
Study 14601477 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated protein C resistance (APC-R)
Number of subjects: 29
Study 14601477 — intervention group
Group type: EXPERIMENTAL
Intervention: Leiden mutation detection by PCR
Number of subjects: 29
Study 10954888 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent combination antiretroviral therapy
Number of subjects: 10
Study 9004781 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc Acexamate (600 mg/d)
Number of subjects: 199
Study 9004781 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (40 mg/d)
Number of subjects: 199
Study 1284003 — intervention group
Group type: COMPARATOR
Intervention: Transurethral incision of the prostate (TUI, n = 29)
Number of subjects: 60
Study 1284003 — intervention group
Group type: COMPARATOR
Intervention: Transurethral prostatectomy (TURP, n = 31)
Number of subjects: 60
Study 1284003 — intervention group
Group type: COMPARATOR
Intervention: Both operations (TURP and TUI)
Number of subjects: 60
Study 6398312 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin administered subcutaneously (s.c.)
Number of subjects: 0
Study 6398312 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin administered intravenously (i.v.)
Number of subjects: 0
Study 6398312 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 6398312 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (both routes)
Number of subjects: 0
Study 29863444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup condition including gay and lesbian individuals
Number of subjects: 90
Study 29863444 — intervention group
Group type: COMPARATOR
Intervention: Outgroup condition including gay and lesbian individuals
Number of subjects: 90
Study 29932784 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 245
Study 29932784 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based mindfulness-based cognitive therapy (eMBCT)
Number of subjects: 245
Study 29932784 — intervention group
Group type: EXPERIMENTAL
Intervention: eMBCT
Number of subjects: 245
Study 29932784 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (MBCT and eMBCT)
Number of subjects: 245
Study 27503351 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 reduced schedule (2 and 4 months)
Number of subjects: 210
Study 27503351 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 accelerated schedule (2, 3, and 4 months)
Number of subjects: 210
Study 27503351 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 extended schedule (2, 4, and 6 months)
Number of subjects: 210
Study 27503351 — intervention group
Group type: EXPERIMENTAL
Intervention: All schedules (reduced, accelerated, extended)
Number of subjects: 210
Study 24994476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (n = 8)
Number of subjects: 19
Study 24994476 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n = 11)
Number of subjects: 19
Study 21964618 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol rinse
Number of subjects: 48
Study 21964618 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 48
Study 20686486 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 4004
Study 20686486 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 4004
Study 20686486 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 4004
Study 18939907 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 4728
Study 18939907 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 4728
Study 16164506 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional discharge model (TDM) of care with peer support for 1 year and ongoing support from hospital staff
Number of subjects: 390
Study 16164506 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional discharge model (TDM) of care
Number of subjects: 390
Study 16164506 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 390
Study 14515443 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL-BFM 90 protocol chemotherapy for 2 years
Number of subjects: 352
Study 14515443 — intervention group
Group type: COMPARATOR
Intervention: Previous study ALL-BFM 83 protocol
Number of subjects: 352
Study 10795953 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-discrepancy magnitude and salience condition
Number of subjects: 60
Study 10795953 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 8879341 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 to 10 mg)
Number of subjects: 218
Study 8879341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (2.5 to 10 mg)/Hydrochlorothiazide (HCTZ) 6.25
Number of subjects: 218
Study 8879341 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 20 mg)
Number of subjects: 218
Study 8879341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 8879341 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 218
Study 1299488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement
Number of subjects: 86
Study 1299488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 30938233 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's experience with battering scale (WEB-scale)
Number of subjects: 882
Study 30938233 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and socioeconomic factors
Number of subjects: 882
Study 31245907 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod plus corticosteroid (diprospan, intramuscular injection, 25 mg, twice daily for 24 weeks)
Number of subjects: 30
Study 31245907 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod plus corticosteroid
Number of subjects: 30
Study 28912447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting survival based on seven independent prognostic factors (age, tumor stage, tumor size, ALT, ALB, CA 19-9, HBV infection status)
Number of subjects: 1526
Study 25627452 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression socks
Number of subjects: 33
Study 25627452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 23599170 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rehabilitation intervention (12 weeks of exercise training and 1 year of psycho-educational follow-up)
Number of subjects: 196